PreveCeutical Medical (PREV) AI Stock Analysis

• Market Cap: $17.12M
• Dividend Yield: N/A
• Average Volume (3M): 107.10K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.37
• Revenue Growth: N/A
• EPS Growth: -95.83%
• Country: CA
• Employees: 7
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): >-0.01
• Shares Outstanding: 570,649,500
• 10 Day Avg. Volume: 76,230
• 30 Day Avg. Volume: 107,101
• PEG Ratio: 114.24
• Price to Book (P/B): -2.02
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -31.30
• Enterprise Value/Market Cap: 1.25
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -2.37K
• Enterprise Value/Ebitda: -9.50
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 26 Underperform
• Price Target: ―

PreveCeutical Medical's overall stock score is primarily driven by its financial struggles, including a lack of revenue and ongoing financial losses. While technical indicators show some stability, the valuation remains unattractive, and the recent private placement, though positive, doesn't fundamentally change the financial risks.

PreveCeutical Medical Business Overview & Revenue Model

Company Description

PreveCeutical Medical Inc. (PREV) is a biotechnology company focused on developing innovative preventive and curative therapies utilizing both natural and synthetic compounds. The company's core offerings include cannabinoid-based therapies, sol-gel drug delivery technologies, and peptide-based therapeutics targeting various ailments. Operating at the intersection of health sciences and biotechnology, PreveCeutical aims to provide solutions that enhance health and well-being.

How the Company Makes Money

PreveCeutical makes money primarily through the research and development of therapeutic products, which are then licensed or sold to pharmaceutical companies or healthcare providers. The company may also generate revenue through strategic partnerships, collaborations, and possibly government or private grants supporting their innovative research. By progressing their products through clinical trials and obtaining necessary regulatory approvals, PreveCeutical can enter into commercialization agreements or secure funding from partners interested in their pipeline offerings.

PreveCeutical Medical Financial Statement Overview

Summary

PreveCeutical Medical faces significant financial challenges, with no revenue, consistent losses, high leverage, and negative cash flows. These issues highlight the company's struggle for financial stability, typical of early-stage biotech firms relying heavily on external financing while developing their product pipeline.

Income Statement

PreveCeutical Medical has shown no revenue generation for the past few years, with consistent negative gross profit and net income. The lack of revenue growth and persistent losses suggest severe profitability challenges, typical for a biotechnology firm in early stages with high R&D costs but no commercial products yet.

Balance Sheet

The company has a negative stockholders' equity, indicating insolvency, compounded by a high debt-to-equity ratio and total liabilities exceeding total assets. This high leverage poses significant financial risk, reflecting a fragile financial structure.

Cash Flow

Operating cash flow is consistently negative, and free cash flow is also in deficit. Although financing cash flow is positive, indicating external funding, the reliance on financing without generating operational cash raises sustainability concerns.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	-9.06K	-10.10K	-9.86K	-9.89K	-5.09K	-75.17K
EBITDA	-2.26M	-837.46K	-955.09K	-1.23M	-1.28M	-3.09M
Net Income	-2.60M	-1.17K	-1.27M	-1.48M	-1.73M	-3.80M
Balance Sheet
Total Assets	361.65K	225.66K	181.51K	189.14K	161.20K	302.45K
Cash, Cash Equivalents and Short-Term Investments	4.26K	59.14K	1.43K	5.62K	16.06K	156.44K
Total Debt	4.55M	4.46M	3.83M	3.23M	2.93M	3.01M
Total Liabilities	7.52M	6.86M	5.96M	4.82M	4.27M	3.91M
Stockholders Equity	-7.20M	-6.64M	-5.78M	-4.64M	-4.10M	-3.60M
Cash Flow
Free Cash Flow	-903.56K	-428.49K	-296.97K	-222.64K	-481.59K	61.94K
Operating Cash Flow	-842.72K	-426.69K	-296.97K	-222.64K	-426.39K	64.59K
Investing Cash Flow	-60.85K	-1.80K	0.00	850.00	-52.70K	-2.65K
Financing Cash Flow	908.61K	487.64K	293.62K	211.72K	136.75K	184.46K

PreveCeutical Medical Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.03
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:PREV, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 44.50 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:PREV.

PreveCeutical Medical Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CURA	56 Neutral	C$3.14B	-8.93	-28.04%	―	-2.64%	1.65%
PREV	26 Underperform	$17.12M	―	21.59%	―	―	-95.83%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

PreveCeutical Medical Corporate Events

PreveCeutical Initiates $300,000 Private Placement to Bolster Operations

PreveCeutical Medical Inc. has announced a non-brokered private placement of up to 10 million units at $0.03 per unit, aiming to raise gross proceeds of up to $300,000. The proceeds will be used for paying outstanding payables, operating expenses, and general working capital. This strategic financial maneuver could potentially strengthen the company’s operational capabilities and enhance its market positioning in the health sciences industry, subject to certain conditions including CSE approval.

BioGene Therapeutics to Showcase Innovations at JP Morgan Healthcare Conference

PreveCeutical Medical Inc.’s subsidiary, BioGene Therapeutics, has announced its participation in the 43rd JP Morgan Healthcare Conference, aiming to showcase its work in metabolic health and gene-based treatments. The participation of BioGene’s leadership team at this prestigious event underscores the company’s commitment to advancing its position in the life sciences industry and highlights its ongoing research efforts, particularly in addressing diabetes and obesity through innovative therapies.

PreveCeutical Enhances Leadership with Dr. Barry Ticho

PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Dr. Barry Ticho to its Scientific Advisory Board, leveraging his seasoned expertise in drug development and biotechnology. Dr. Ticho’s impressive career includes leadership roles at Stoke Therapeutics and contributions to companies like Verve and Moderna, marking significant advancements in treating various diseases. This strategic appointment is expected to enhance BioGene’s initiatives in developing innovative therapies.

PreveCeutical Medical Strengthens Leadership with New Appointment

PreveCeutical Medical Inc.’s subsidiary, BioGene Therapeutics, has appointed Dr. Brian Gallagher, Jr. to its Corporate Advisory Board, bringing his expertise in venture capital and corporate development. Gallagher’s extensive experience in biotech investments and successful leadership in high-profile exits, like the acquisition of Translate Bio by Sanofi, is expected to drive BioGene’s growth in innovative therapies.

PreveCeutical Medical Welcomes Stephen Glover to Board

PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Stephen Glover to its Board of Directors, leveraging his extensive leadership experience in the biopharma industry to advance their mission of developing groundbreaking therapies. Glover, known for his successful track record in corporate strategy and financial management, is expected to significantly contribute to the company’s growth and innovation.

PreveCeutical Welcomes Expert to Boost Health Research

PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Professor Mirela Delibegovic to its Scientific Advisory Board, enhancing their expertise in metabolic health research. Her extensive background in diabetes and obesity research is expected to significantly contribute to BioGene’s innovative therapeutic programs.

PreveCeutical’s BioGene Announces Key Leadership Appointments

PreveCeutical Medical’s subsidiary, BioGene Therapeutics, appoints Dr. Linnea Olofsson as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer to advance its drug and gene delivery technologies. These strategic appointments are expected to drive innovation and growth in the life sciences sector, positioning the company for future success.

PreveCeutical Finalizes BioGene Asset Deal

PreveCeutical Medical has successfully closed a transaction involving the sale of intellectual property assets to its subsidiary, BioGene Therapeutics, for a total of USD$1,353,227. The deal includes a cash payment and the issuance of 16 million common shares of BioGene, with plans to distribute some of these shares to shareholders. This strategic move could potentially enhance PreveCeutical’s financial position and shareholder value.

PreveCeutical’s BioGene Names New President

PreveCeutical Medical’s subsidiary, BioGene Therapeutics, has appointed Dr. Mariya Georgieva as President to lead advancements in siRNA therapy for diabetes and obesity. Dr. Georgieva brings valuable experience from AstraZeneca, enhancing BioGene’s research capabilities in metabolic health and gene-based treatments.